Background: Elderly patient with community-acquired pneumonia is the leading infectious cause of death. During the clinical diagnosis and treatment, some elderly patients do not have typical clinical symptoms .Therefore establishment of safe and effective diagnosis, prognostic assessment systems is important for clinicians. Objective: To evaluate the diagnostic and prognostic value of the neutrophil CD64(nCD64) in elderly patients with community-acquired pneumonia. Methods: One hundred and twenty-eight elderly patients(≥65year) diagnosed with community-acquired pneumonia from December 2018 to December 2020. All patients were further subdivided into two groups: Non severe community-acquired pneumonia(N-SCAP) group and severe community-acquired pneumonia (SCAP)group. nCD64 index, procalcitonin (PCT) level, C-reactive protein (CRP) level, White blood cell (WBC) counts and Neutrophil (NEUT) absolute counts were obtained and CURB-65 scores were calculated for each patient. Results: The nCD64, CRP ,PCT, WBC,NEUT levels,CURB-65 score were higher in severe community-acquired pneumonia group patients. The nCD64, CRP, PCT levels ,CURB-65 score were higher in non-survivors. The receiver operating characteristic (ROC) curve of nCD64 was higher than those of CRP, PCT, WBC, NEUT levels for diagnosing infection. The AUC of nCD64 for predicting 28-day mortality in community-acquired pneumonia was significantly higher than those of CRP ,PCT, WBC and NEUT. The AUC of nCD64 combined with CURB-65 score was significantly higher than that of CRP, PCT, WBC and NEUT parameter combined with CURB-65 score for predicting 28-day mortality. Conclusions: The neutrophil CD64 index is a valuable biomarker for diagnosis of infection and prognostic evaluation in elderly patients (≥65 year) with community-acquired pneumonia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.